論文

査読有り
2014年9月

High-dose concurrent chemo-proton therapy for Stage III NSCLC: preliminary results of a Phase II study

JOURNAL OF RADIATION RESEARCH
  • Yoshiko Oshiro
  • ,
  • Toshiyuki Okumura
  • ,
  • Koichi Kurishima
  • ,
  • Shinsuke Homma
  • ,
  • Masashi Mizumoto
  • ,
  • Hitoshi Ishikawa
  • ,
  • Masataka Onizuka
  • ,
  • Mitsuaki Sakai
  • ,
  • Yukinobu Goto
  • ,
  • Nobuyuki Hizawa
  • ,
  • Yukio Sato
  • ,
  • Hideyuki Sakurai

55
5
開始ページ
959
終了ページ
965
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1093/jrr/rru034
出版者・発行元
OXFORD UNIV PRESS

The aim of this report is to present the preliminary results of a Phase II study of high-dose (74 Gy RBE) proton beam therapy (PBT) with concurrent chemotherapy for unresectable locally advanced non-small-cell lung cancer (NSCLC). Patients were treated with PBT and chemotherapy with monthly cisplatin (on Day 1) and vinorelbine (on Days 1 and 8). The treatment doses were 74 Gy RBE for the primary site and 66 Gy RBE for the lymph nodes without elective lymph nodes. Adapted planning was made during the treatment. A total of 15 patients with Stage III NSCLC (IIIA: 4, IIIB: 11) were evaluated in this study. The median follow-up period was 21.7 months. None of the patients experienced Grade 4 or 5 non-hematologic toxicities. Acute pneumonitis was observed in three patients (Grade 1 in one, and Grade 3 in two), but Grade 3 pneumonitis was considered to be non-proton-related. Grade 3 acute esophagitis and dermatitis were observed in one and two patients, respectively. Severe (>= Grade 3) leukocytopenia, neutropenia and thrombocytopenia were observed in 10 patients, seven patients and one patient, respectively. Late radiation Grades 2 and 3 pneumonitis was observed in one patient each. Six patients (40%) experienced local recurrence at the primary site and were treated with 74 Gy RBE. Disease progression was observed in 11 patients. The mean survival time was 26.7 months. We concluded that high-dose PBT with concurrent chemotherapy is safe to use in the treatment of unresectable Stage III NSCLC.

Web of Science ® 被引用回数 : 37

リンク情報
DOI
https://doi.org/10.1093/jrr/rru034
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/24864278
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000342223100015&DestApp=WOS_CPL
ID情報
  • DOI : 10.1093/jrr/rru034
  • ISSN : 0449-3060
  • eISSN : 1349-9157
  • PubMed ID : 24864278
  • Web of Science ID : WOS:000342223100015

エクスポート
BibTeX RIS